Receive this email from someone else? Subscribe now!
09/24/2014 10:00 AM EDT
Prostate cancer is the second most common cause of cancer-related deaths among American men.
This year marks the tenth anniversary of the approval of docetaxel, the first chemotherapy for metastatic prostate cancer that showed a survival benefit. Since docetaxel, five additional therapies have been approved, and all of them have shown improvements in survival.
Read the Consumer Update to learn more about this prevalent disease and how the FDA is working to help prolong the lives of those suffering from it.
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
